 Because of the overprescription of ADHD medication during the Covid lockdown by companies like Cerebral and Done, who are now under investigation by the DEA and FDA, there is a shortage of Adderall. This has had a cascading effect onto the other ADHD medications such as the methylphenidate class, as providers try to find alternatives for their clients. A report from Carlat Psychiatry projects the adderall shortage to last until March 2023, perhaps longer (Aiken & Newsome, 2023). In addition to this, the Wall Street Journal has reported the American Professional Society of ADHD and Related Disorders is working with the American Psychiatric Association to provide official guidelines for diagnosis and treatment of ADHD in adults (2022). Up to this point, guidelines have only been for children up to the age of 18. Adult guidelines are slated for release sometime in 2023. I expect more stingent guidelines will be provided in order to protect the public from overprescription of stimulants. The article in The WSJ quoted a concerned provider stating this may be another opioid epidemic. Resources:
Comments are closed.
|